The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 1033-1049

  Brenner, Darren M ^a   Moeller, Matthew J ^b   Chey, William D ^c   Schoenfeld, Philip S ^c,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Department of Internal Medicine ^*  (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLORASTAT; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VSL3;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ATHEROSCLEROSIS; BIFIDOBACTERIUM; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM LONGUM INFANTIS; BLOATING; BREVIBACILLUS BREVIS; CLINICAL TRIAL; CYSTITIS; DATA ANALYSIS; DATA BASE; DATA EXTRACTION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EPISTAXIS; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINAL DYSMOTILITY; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS HELVETICUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; META ANALYSIS; METHODOLOGY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPIONIBACTERIUM FREUDENREICHII; RESPIRATORY TRACT DISEASE; REVIEW; SKIN INFLAMMATION; STREPTOCOCCUS THERMOPHILUS; SYSTEMATIC REVIEW; TENOSYNOVITIS; THORAX PAIN; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; IRRITABLE BOWEL SYNDROME; TREATMENT OUTCOME;

BIFIDOBACTERIUM; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS; TREATMENT OUTCOME;

EID: 65449172901     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.25     Document Type: Review

References (46)

1. Hungin APS, Chang L, Locke GR et al. Irritable bowel Syodrome in the United States: Prevalence, symptoms patteros and impact. Aliment Pharmacol Ther 2005;21:1365-75.
2. Drossman DA, Camilleri M, Mayer EA et al. AGA technical review on irritable bowel syndrome. Gastroenterol 2002;123:2108-31.
3. Rajagopalan M, Kuriao G, Jobo J. Symptom relief with Amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998;13:738-41.
4. Muller-Lissner SA. Fumagalli I. Bardhan KD et al. Tegaserod, a 5HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-66.
5. Camilleri M, Northcutt AR, Kong S et al. Efficacy and safety of Alosetron in women with irritable bowel syndrome: A randomized, placebo-controlled trial. Lancet 2000;355:1035-40.
6. Pimentel M, Chow U. Lin HC. Normalization of Lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-9.
7. Pimentel M, Park S, Mirocha J et al. The effect of a non-absorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome. knn Intern Med 2006;145:557-63.
8. Horwitz B, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001;344:t846-50.
9. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? I Clin Gastroenterol 1997;25:653.
10. Mimura T, Rizzello F. Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108.
11. Gionchetti P, Rizzello F, Helwig U et al.. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind placebo controlled trial. Gastroenterol 2003;124:1202.
12. Surawicz CM, McFarland LV, Elmer G et al. Treatment of recurrent Clostridium dithcile colitis with Vancomycin and Saccharamyces boulardii. Am J Gastroenierol 1989;84:1285-7.
13. Johansson ML, Molin G, Jeppsson B et al. Administration of different Lactabacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Unviron Microbiol 1993;59:15-20.
14. Alander M, Korpela R, Saxelin M et al. Recovery of Lactobacillus rhamnasus GG from human colonic biopsies. Lett Appl Microbiol 1997;24:361-4.
15. Silva M, Jacobus NV, Deneke C et al., Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987;31: 131-1233.
16. Patbmakanthan 5, Li C, Cowie J et al. Lactobacillus plantaruns 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenierol Hepaiol 2004;1 9:166-73.
17. Borruel N, Casellas F, Antolin Met al. Lffects of non-pathogenic bacteria on cytokine secretion by human intestinal mucosa. Am I Gastroenterol 2003;98:865-70.
18. Menard 5, Candalh C, Bombou JC et al. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 2004;53:821-8.
19. O'Mahony L. McCarthy J. Kelly Pet al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterol 2005;128:41-551.
20. Floch MH. Use of diet and probiotic therapy in the irritable bowel syndrome. J Clin Gasiroenterol 2005;39:S243-6.
21. Manning AR Thompson WG, Heaion KW et al. Towards positive diagnosis of the irritable bowel. BMJ 1979;2:653-4.
22. Thompson WG, Longstretb GF, Orossman OA et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45:1143-7.
23. Veldhuyzen van Zanien SJO, Talley NJ, Byizer P et al. Oesign of treatment trails for functional gastrointestinal disorders. Gut 1999;45 (suppl II): 1169-77.
24. The Cochrane Collaboration Meta-analysis of continuous data: Measuring the effect of treatment; 2002.
25. Kim HJ, Camilleri M, McKinzie S et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
26. Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687-96.
27. Bittner AC. Croffut RIvI, Stranahan MC. Prescript-Assist probioticprebiotic treatment for irritable bowel syndrome: A methodologically oriented, 2-week randomized placebo-controlled, double-blind clinical study. Chn Ther 2005;27:755-61.
28. Tsuchiya J, Barreto R, Okura R et al. Single blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Ois 2004;5:169-74.
29. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. Clin Gastroenterol 2004;38:S 104-6.
30. Kajander K, Hatakka K, Poussa T et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-94.
31. Kajander K, Myllyluoma U. Rajili-Stojanovics Met al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008;27:48-57.
32. Niv E, Naftali T, Hallak R et al. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-A double blind placebo-controlled, randomized stody. Clin Nutr 2005;24:925-31.
33. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized placebo-controlled crossover stody. Digest Liv Dis 2000;32:284-301.
34. Halpern GM, Prindivifle T, Blankenborg M et al.. Treatment of irritable bowel syndrome with Lacteol-Fort: A randomized, double-blind, cross-over trial. Am J Gastroenterol 1996;91:1579-85.
35. Nobaek 5, Johansson ML, Molin G et al. Alteration of intestinal microllora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am I Gastroenterol 2000;95:1231-8.
36. Niedzielin K, Kordecki H, Birkenfeld B. A controlled double-blind, randomized study on the efficacy of Lactobacillus plaataruos 299V in patients with irritable bowel syndrome. Lur J Gastroenterol Hepatol 2001;13: 1143-7.
37. Sen 5, Mullan MM, Parker TJ et al. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-20.
38. Whorwell P1, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90.
39. Quigley EM, Whorwell P1, Shanahan F et al. Safety and tolerability of the probiotic organism Bifidobacterium infantis 35624: Clinical experience and molecular basis. Gastroenterol 2006;130 (Suppl 2) (A-493).
40. Guyonnet D, Cbassany 0, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26:475-86.
41. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin lb in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523-6.
42. Tornblom H, Lindberg G, Nyberg B et al. Full-thickness biopsy of the jejunum reveals inflammation and coterie neuropathy in irritable bowel syndrome. Gastroenterol 2002;123:t972-9.
43. O'Sullivan M, Clayton N, Breslin NP et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Mot 2000;12:449-57.
44. Barbara G, Stanghellini Sc Dc Giorgio Ret al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterol 2004;126:693-702.
45. McCarthy I, O'Mahony L, O'Callaghan L et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cvtokine balance. Gut 2003;52:975-80.
46. Irvine U, Whitehead WU, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterol 2006; 130:1538-51.